DEVELOPMENTAL RESEARCH PROGRAM
发展研究计划
基本信息
- 批准号:8561363
- 负责人:
- 金额:$ 1.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-09-20 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:Basic ScienceChronic Lymphocytic LeukemiaClinicClinicalClinical ResearchClinical TrialsCollaborationsDataDevelopmentDisciplineFosteringFundingGenerationsGoalsGrantHumanIncidenceInstitutionLaboratory StudyLeadLymphomaMalignant NeoplasmsPatientsPeer ReviewPhasePopulation SciencesPopulation StudyResearchResearch PersonnelResearch Project GrantsResourcesSpecialized Program of Research ExcellenceTestingTranslatingTranslational ResearchUniversitiesbaseinnovationmortalityprogramssound
项目摘要
The goal ofthe University of lowa / Mayo Clinic Lymphoma SPORE (UI/MC SPORE) Developmental
Research Program is to support innovative, scientifically sound projects that investigate a question pertaining
to translational lymphoma research. This program was highly successful with past and current support over
the past 4 years going to 13 developmental research projects. Three of these projects have received
external, peer-reviewed NCI funding or a fundable priority score, 3 received a second year of funding, and 3
provided data that was instrumental for the major research projects selected for this renewal. The
Developmental Research Program will provide up to $50,000 for one year ($25,000 from UI/MC SPORE
funds and a matching $25,000 from institutional resources) to each of four projects each year with the
possibility of a second year of support based on progress. It is anticipated that support of developmental
research projects will continue to result in the generation of new hypotheses that will be tested in full UI/MC
SPORE-sponsored projects or through peer reviewed external grant support. The long-term goal of the
UI/MC SPORE program is to translate the findings generated by developmental projects into a reduction in
the incidence and mortality rates of lymphoma. More specifically, the objectives ef the Developmental
Research Program are to: (1) encourage innovative translationally-relevant laboratory, population and
clinical studies in lymphoma and chronic lymphocytic leukemia; (2) foster extensive collaboration between
basic science, population science and clinical disciplines in translational research in lymphoma; and, (3)
generate new hypotheses to be tested in large-scale research projects or clinical trials that may lead to
significant reduction of lymphoma incidence and mortality. Brief outlines of four developmental research
projects from investigators at the University of lowa and the Mayo Clinic are included to demonstrate the
depth and breadth of ongoing research that can be applied to the translational lymphoma research at these
institutions and could be eligible for UI/MC SPORE Developmental Program support.
爱荷华大学/梅奥临床淋巴瘤孢子(UI/MC孢子)的发展目标
研究计划是支持创新的、科学合理的项目,这些项目调查与
转化性淋巴瘤研究。该计划在过去和现在的支持下非常成功
在过去的4年里,将有13个发展研究项目。其中三个项目已经收到
外部,同行评审的NCI资助或可资助的优先分数,3获得第二年资助,3
提供了对选定进行此次更新的主要研究项目有用的数据。这个
发展研究计划将提供高达50,000美元的一年(25,000美元来自UI/MC孢子
资金和来自机构资源的25,000美元),每年向四个项目的每个项目提供
根据进展情况,有可能提供第二年的支助。预计对发展的支持
研究项目将继续产生新的假设,这些假设将在完整的用户界面/MC中进行测试
孢子赞助的项目或通过同行审查的外部赠款支助。中国的长期目标是
UI/MC孢子计划是将开发项目产生的结果转化为
淋巴瘤的发病率和死亡率。更具体地说,发展的目标
研究计划旨在:(1)鼓励与翻译相关的创新实验室、人口和
淋巴瘤和慢性淋巴细胞白血病的临床研究;(2)促进
淋巴瘤转化研究中的基础科学、人口科学和临床学科;以及,(3)
生成新的假设,以在大规模研究项目或临床试验中进行测试,这可能会导致
淋巴瘤发病率和死亡率显著降低。四项发展性研究概述
来自爱荷华大学和梅奥诊所的研究人员的项目包括在内,以证明
可应用于转化性淋巴瘤研究的正在进行的研究的深度和广度
并有资格获得UI/MC孢子开发计划支持。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Steven R Lentz其他文献
Steven R Lentz的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Steven R Lentz', 18)}}的其他基金
Vascular Mechanisms in Homocysteinemia and Atherosclerosis
同型半胱氨酸血症和动脉粥样硬化的血管机制
- 批准号:
8232154 - 财政年份:2009
- 资助金额:
$ 1.01万 - 项目类别:
Vascular Mechanisms in Homocysteinemia and Atherosclerosis
同型半胱氨酸血症和动脉粥样硬化的血管机制
- 批准号:
8033673 - 财政年份:2009
- 资助金额:
$ 1.01万 - 项目类别:
Vascular Mechanisms in Homocysteinemia and Atherosclerosis
同型半胱氨酸血症和动脉粥样硬化的血管机制
- 批准号:
7651987 - 财政年份:2009
- 资助金额:
$ 1.01万 - 项目类别:
Vascular Mechanisms in Homocysteinemia and Atherosclerosis
同型半胱氨酸血症和动脉粥样硬化的血管机制
- 批准号:
7808077 - 财政年份:2009
- 资助金额:
$ 1.01万 - 项目类别:
Fourteenth Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology
第十四届动脉硬化、血栓形成和血管生物学年会
- 批准号:
8529113 - 财政年份:2006
- 资助金额:
$ 1.01万 - 项目类别:
STRUCTURE AND FUNCTION OF CEREBRAL BLOOD VESSELS IN HYPERHOMOCYSTEINEMIA
高同型半胱氨酸血症脑血管的结构和功能
- 批准号:
6618775 - 财政年份:2002
- 资助金额:
$ 1.01万 - 项目类别:
Mechanisms of Vascular Dysfunction in Homocysteinemia
同型半胱氨酸血症血管功能障碍的机制
- 批准号:
7250273 - 财政年份:2000
- 资助金额:
$ 1.01万 - 项目类别:
Mechanisms of Vascular Dysfunction in Homocysteinemia
同型半胱氨酸血症血管功能障碍的机制
- 批准号:
7089066 - 财政年份:2000
- 资助金额:
$ 1.01万 - 项目类别:
相似海外基金
Define the oncogenic role of METTL3 in the pathogenesis of chronic lymphocytic leukemia
定义 METTL3 在慢性淋巴细胞白血病发病机制中的致癌作用
- 批准号:
10717803 - 财政年份:2023
- 资助金额:
$ 1.01万 - 项目类别:
A combination strategy to target pathophysiology of chronic lymphocytic leukemia
针对慢性淋巴细胞白血病病理生理学的组合策略
- 批准号:
10577652 - 财政年份:2023
- 资助金额:
$ 1.01万 - 项目类别:
Predictive markers for personalized therapy in chronic lymphocytic leukemia
慢性淋巴细胞白血病个体化治疗的预测标记
- 批准号:
10591089 - 财政年份:2023
- 资助金额:
$ 1.01万 - 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
- 批准号:
10566833 - 财政年份:2023
- 资助金额:
$ 1.01万 - 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
- 批准号:
10987699 - 财政年份:2023
- 资助金额:
$ 1.01万 - 项目类别:
Tracing the Evolution of Chronic Lymphocytic Leukemia to Richter's Syndrome: Defining Transformation
追踪慢性淋巴细胞白血病向里氏综合征的演变:定义转变
- 批准号:
10425791 - 财政年份:2022
- 资助金额:
$ 1.01万 - 项目类别:
Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia
优化针对先前未治疗的高风险慢性淋巴细胞白血病的新药联合疗法
- 批准号:
10522611 - 财政年份:2022
- 资助金额:
$ 1.01万 - 项目类别:
Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia
优化针对先前未治疗的高风险慢性淋巴细胞白血病的新药联合疗法
- 批准号:
10705268 - 财政年份:2022
- 资助金额:
$ 1.01万 - 项目类别:
The genetic and epigenetic etiology of progression from the precursor state to chronic lymphocytic leukemia (CLL)
从前体状态进展为慢性淋巴细胞白血病(CLL)的遗传和表观遗传病因学
- 批准号:
10369783 - 财政年份:2022
- 资助金额:
$ 1.01万 - 项目类别:
The genetic and epigenetic etiology of progression from the precursor state to chronic lymphocytic leukemia (CLL)
从前体状态进展为慢性淋巴细胞白血病(CLL)的遗传和表观遗传病因学
- 批准号:
10699957 - 财政年份:2022
- 资助金额:
$ 1.01万 - 项目类别: